Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Aug 20;16(1):660.
doi: 10.1186/s12885-016-2692-4.

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

Trinidad Dierssen-Sotos  1   2 , Inés Gómez-Acebo  3   4 , María de Pedro  5 , Beatriz Pérez-Gómez  3   6   7 , Sonia Servitja  8   9 , Víctor Moreno  3   10 , Pilar Amiano  3   11 , Tania Fernandez-Villa  12   13 , Aurelio Barricarte  14   15 , Adonina Tardon  3   16 , Marian Diaz-Santos  17   18 , Rosana Peiro-Perez  3   19 , Rafael Marcos-Gragera  20 , Virginia Lope  3   6   7 , Esther Gracia-Lavedan  3   21   22 , M Henar Alonso  3   10 , Maria Jesus Michelena-Echeveste  23 , Andrés Garcia-Palomo  24 , Marcela Guevara  3   14   15 , Gemma Castaño-Vinyals  3   21   22   25 , Nuria Aragonés  3   6   7 , Manolis Kogevinas  3   21   22 , Marina Pollán  3   6   7 , Javier Llorca  3   4
Affiliations
Multicenter Study

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

Trinidad Dierssen-Sotos et al. BMC Cancer. .

Abstract

Background: The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors).

Methods: In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics.

Results: In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers.

Conclusion: Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers.

Keywords: Breast cancer; HER2 positive breast cancer; Hormone receptor positive breast cancer; Non-steroidal anti-inflammatory drug; Triple negative breast cancer.

PubMed Disclaimer

References

    1. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18(55):7908–16. doi: 10.1038/sj.onc.1203286. - DOI - PubMed
    1. Harris RE, Alshafie GA, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000;20(8):2101–3. - PubMed
    1. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000;83(1):112–20. doi: 10.1054/bjoc.2000.1119. - DOI - PMC - PubMed
    1. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Women’s Health Initiative. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 2003;63(18):6096–101. - PubMed
    1. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Ziogas A, Ross RK. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005;97(11):805–12. doi: 10.1093/jnci/dji140. - DOI - PubMed

Publication types

Substances